Predictors of residual disease after breast-conserving surgery.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 168-168
Author(s):  
Sanjay Aneja ◽  
Donald R. Lannin ◽  
Brigid K. Killelea ◽  
Nina Ruth Horowitz ◽  
Anees B. Chagpar
Keyword(s):  
Tumor Size ◽  
Lymphovascular Invasion ◽  
Residual Disease ◽  
Breast Conserving Surgery ◽  
Invasive Disease ◽  
Invasive Cancer ◽  
Outcome Variable ◽  
Routine Practice ◽  
Breast Cancers

168 Background: Locoregional failure after breast conserving surgery (BCS) is often due to undetected residual disease, and the risk of such residual disease frequently guides management. We sought to determine clinical and pathologic factors correlating with the finding of residual invasive cancer and/or DCIS in patients undergoing BCS. Methods: We performed a retrospective cohort study for all invasive and in situ breast cancer treated with BCS at a single institution in 2009. The main outcome variable of interest was residual disease determined by pathologic examinations of cavity shave margins or reexcision. Chart review and statistical analyses were performed to evaluate clinical and pathological factors correlating with residual DCIS or invasive cancer. Results: 256 in situ or invasive breast cancers were treated with BCS in 2009. Of these, 207 (80.9%) underwent additional resection either for close margins or as routine practice. These formed the cohort of interest for this study. 39 patients (18.8%) had residual DCIS and 22 (10.6%) had residual invasive disease. Age, race, histology, ER, PR, her-2-neu and margin distance for invasive disease did not predict the finding of residual DCIS nor invasive cancer. Lymphovascular invasion, while not predicting residual DCIS, was correlated with the finding of residual invasive disease (28.0% vs. 7.9%, p=0.007). Margin distance for DCIS was not predictive of residual invasive cancer but was predictive of residual DCIS. 33.8% of lesions with DCIS margins <1mm were associated with residual DCIS, while 3.4% of those with DCIS margins >5mm were associated with residual in situ disease (p=0.002). Increasing tumor size for invasive and in situ disease were associated with residual DCIS (median 19.5 vs. 13.0 mm, p=0.001 and 22.5 vs. 15.0 mm, p<0.001, respectively); however, neither size component was associated with residual invasive disease. Conclusions: While margin distance and tumor size are associated with residual DCIS in patients undergoing BCS, these are not correlated with residual invasive disease. Conversely, the finding of lymphovascular invasion predicts residual invasive cancer, but not DCIS. These factors may aid in risk stratification of patients and guide postoperative management.

Accuracy of breast MRI in predicting pathologic tumor size.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1109-1109 ◽  
Author(s):  
Kimberly Anne Caprio ◽  
Anees B. Chagpar ◽  
Regina Hooley ◽  
Fattaneh Tavassoli ◽  
Helen Honarpishe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Size ◽  
Breast Mri ◽  
Invasive Disease ◽  
Lesion Size ◽  
Planning Tool ◽  
Imaging Data ◽  
Factors Affecting ◽  
Modest Correlation

1109 Background: MRI use as a preoperative planning tool is increasing in women with breast cancer, yet the correlation between MRI and pathologic size of cancers is unclear. The purpose of this study was to determine the accuracy of MRI in predicting pathologic tumor size, and factors that affect this correlation. Methods: Clinicopathologic and imaging data from 84 patients diagnosed with invasive or in situ breast cancer from September 2010 to October 2011 who had preoperative MRI were reviewed. 12 patients who had neoadjuvant chemotherapy were excluded. MRI detected 147 lesions in the remaining 72 patients. Concordance between MRI and pathology size was determined using Spearman rho coefficients, and factors affecting the accuracy of MRI in predicting tumor size within +/- 0.5 cm were determined. Results: There was a modest correlation between MRI and pathology size for all MRI detected lesions (benign or malignant) with a Spearman coefficient of 0.53. Of the 147 MRI detected lesions, 45 (30.6%) had pathologic and MRI size correlating within +/- 0.5 cm; 76 (51.7%) were overestimated (>0.5cm) by MRI, and 26 (17.7%) were underestimated (>0.5cm). 101 (68.7%) of the 147 lesions were found to be malignant (either with invasive disease or DCIS). In this subgroup, 35 lesions (34.7%) had an MRI size within +/- 0.5 cm of the pathologic size; 40 (39.6%) were overestimated by MRI and 26 (25.7%) were underestimated. Patient age, tumor histology, LVI and grade did not predict concordance between pathologic and MRI size. However, small MRI lesion size more accurately correlated with pathologic tumor size. While 51.1% of tumors that had concordant MRI and pathologic findings within 0.5 cm were <1 cm on MRI, no tumor found to be > 5 cm on MRI was within +/-0.5 cm on final pathology (p=0.001). Conclusions: MRI accurately predicts pathologic tumor size only when the size of the lesion on MRI is <1 cm.

scholarly journals Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Hung-Wen Lai ◽  
Yi-Lin Chang ◽  
Shou-Tung Chen ◽  
Yu-Jun Chang ◽  
Wen-Pei Wu ◽  
...  
Keyword(s):  
Lymph Node ◽  
Ductal Carcinoma In Situ ◽  
Tumor Size ◽  
Predictive Value ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Mri ◽  
Invasive Cancer ◽  
Node Negative

Abstract Background The optimal axillary lymph node (ALN) management strategy in patients diagnosed with ductal carcinoma in situ (DCIS) preoperatively remains controversial. The value of breast magnetic resonance imaging (MRI) to predict ALN metastasis pre-operative DCIS patients was evaluated. Methods Patients with primary DCIS with or without pre-operative breast MRI evaluation and underwent breast surgery were recruited from single institution. The value of breast MRI for ALN evaluation, predictors of breast and ALN surgeries, upgrade from DCIS to invasive cancer, and ALN metastasis were analyzed. Results A total of 682 cases with pre-operative diagnosis of DCIS were enrolled in current study. The rate of upgrade to invasive cancer were found in 34.2% of specimen, and this upgrade rate is 23% for patients who received breast conserving surgery and 40.7% for mastectomy (p < 0.01). Large pre-operative imaging tumor size and post-operative invasive component were risk factors to ALN metastasis. Breast MRI had 53.8% sensitivity, 77.8% specificity, 14.9% positive predictive value, 95.9% negative predictive value (NPV), and 76.2% accuracy to predict ALN metastasis in pre-OP DCIS patients. In MRI node-negative breast cancer patients with MRI tumor size < 3 cm, the NPV was 96.4%, and all these false-negative cases were N1. Pre-OP diagnosed DCIS patients with MRI tumor size < 3 cm and node negative suitable for BCS could safely omit SLNB if whole breast radiotherapy is to be performed. Conclusion Breast MRI had high NPV to predict ALN metastasis in pre-OP DCIS patients, which is useful and could be provided as shared decision-making reference.

Discordance Between Pathologic and Radiologic Tumor Size on Breast MRI May Contribute to Increased Re-excision Rates

2011 ◽  
Vol 77 (10) ◽  
pp. 1361-1363 ◽  
Author(s):  
Lindi H. Vanderwalde ◽  
Catherine M. Dang ◽  
Catherine Bresee ◽  
Edward H. Phillips
Keyword(s):  
Tumor Size ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Mri ◽  
Breast Cancers ◽  
Breast Center ◽  
Significant Difference ◽  
Preoperative Breast Mri ◽  
The Impact

Preoperative breast MRI does not decrease re-excision rates in patients who undergo lumpectomy. We evaluated concordance of tumor size on MRI and pathologic size in patients who underwent re-excision of margins after lumpectomy. A retrospective review of patients at the Cedars-Sinai Breast Center who received breast MRI was performed. We found that MRI was performed before lumpectomy in 136 patients. Mean age was 55.2 years (standard deviation ± 12.6). Re-excision occurred in 34 per cent (n = 46). Of those undergoing re-excision, 35 per cent (16/46) were re-excised for ductal carcinoma in situ (DCIS) at the lumpectomy margin. There was no significant difference between radiologic and pathologic size of the tumor (1.94 vs 2.12 cm; P = 0.159). In those who underwent re-excision, the radiologic size was underestimated compared with the pathologic size (2.01 vs 2.66 cm; P = 0.032). Patients with pure DCIS lesions (n = 9) also had smaller radiologic tumor size compared with pathologic (0.64 vs 2.88 cm; P = 0.039), and this difference trended toward significance in those who underwent re-excision (0.55 vs 3.50 cm; P = 0.059). Discordance between tumor size on MRI and pathologic size may contribute to re-excisions in patients who undergo lumpectomy. The limitations of breast MRI to evaluate the extent of DCIS surrounding many breast cancers, and the impact on re-excision rates, should be further evaluated.

Use of local flaps in the preservation of fecal continence following resection of perianal neoplasias

1993 ◽  
Vol 3 (5) ◽  
pp. 318-323 ◽  
Author(s):  
D. P.J Barton ◽  
M. S. Hoffman ◽  
W. S. Roberts ◽  
J. V. Fiorica ◽  
M. A. Finan ◽  
...  
Keyword(s):  
Anal Sphincter ◽  
External Anal Sphincter ◽  
Preoperative Assessment ◽  
Invasive Disease ◽  
Fecal Continence ◽  
Invasive Cancer ◽  
Curative Surgery ◽  
Thickness Skin ◽  
Advancement Flaps

The feasibility of achieving curative resection of perianal pre-invasive and invasive lesions with preservation of fecal continence was studied prospectively. Resection of these lesions involved excision of as much as the anterior third of the external anal sphincter. Twenty-two patients had invasive cancer and nine had extensive carcinomain sitususpicious for invasive disease on preoperative assessment. Anal reconstruction consisted of plication of the external anal sphincter and plication of the puborectalis muscles. The perianal/perineal defects were closed using bilateral rhomboid flaps in 21 patients, unilateral rhomboid flaps in five patients and local advancement flaps in five patients. Twenty-eight patients were ultimately continent of feces, although two required further surgery for incontinence. Two of the three incontinent patients had fecal incontinence before surgery. Two patients had recurrence of invasive cancer, neither of which was perineal or perianal. Curative surgery of selected perianal lesions with preservation of fecal continence can be achieved with local resection and reconstruction with the use of local full thickness skin flaps.

Can Radiologic Tumor Size Following Neoadjuvant Therapy Reliably Guide Tissue Resection in Breast Conserving Surgery in Patients with Invasive Breast Cancer?

2020 ◽  
Vol 86 (10) ◽  
pp. 1248-1253
Author(s):  
Sarah Walcott-Sapp ◽  
Marissa K. Srour ◽  
Minna Lee ◽  
Michael Luu ◽  
Farin Amersi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Invasive Breast Cancer ◽  
Tumor Size ◽  
Disease Free Survival ◽  
Positive Margin ◽  
Breast Conserving Surgery ◽  
Breast Cancers ◽  
Positive Margin Rate

Optimum tissue resection volume for patients with invasive breast cancer undergoing breast conserving surgery following neoadjuvant therapy (NAT) is not known. We compared positive margin and in-breast tumor recurrence (IBTR) between 2 groups that were created based on radiologic tumor size (RTS (cm3)) at diagnosis, RTS post-NAT, and volume of tissue resected (VTL): Pre-NAT group, patients with VTL closer to RTS at diagnosis, and post-NAT group, patients with VTL closer to post-NAT RTS. 82 patients with 84 breast cancers treated with NAT between 2007 and 2017 who had pre- and post-NAT imaging were identified from a prospectively maintained database. RTS at diagnosis, RTS post-NAT, and VTL were determined. Clinical and treatment characteristics, IBTR, and disease-free survival (DFS) were compared between pre-NAT (n = 51) and post-NAT (n = 33) groups. Compared to post-NAT patients, pre-NAT patients had smaller RTS at presentation (9.2 vs. 33.5 cm3, P < .001) and post-NAT (1.2 vs. 8.2 cm3, P = .024). At median follow-up of 4 years, there were no differences between groups in pathologic tumor size, positive margin rate, adjuvant therapy, IBTR, or DFS. Resection volumes that matched RTS on post-NAT imaging were not associated with increased positive margins or IBTR. It may be appropriate to use post-NAT imaging to guide lumpectomy volume.

scholarly journals Predictors of Sentinel Lymph Node Metastasis in Postoperatively Upgraded Invasive Breast Carcinoma Patients

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4099
Author(s):  
Chi-Chang Yu ◽  
Yun-Chung Cheung ◽  
Chuen Hsueh ◽  
Shin-Cheh Chen
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Odds Ratio ◽  
Lymphovascular Invasion ◽  
Total Population ◽  
Ductal Carcinoma ◽  
Breast Conserving Surgery ◽  
Positive Slns ◽  
Risk Predictors

Sentinel lymph node (SLN) biopsy (SLNB) usually need not be simultaneously performed with breast-conserving surgery (BCS) for patients diagnosed with ductal carcinoma in situ (DCIS) by preoperative core needle biopsy (CNB), but must be performed once there is invasive carcinoma (IC) found postoperatively. This study aimed to investigate the factors contributing to SLN metastasis in underestimated IC patients with an initial diagnosis of DCIS by CNB. We retrospectively reviewed 1240 consecutive cases of DCIS by image-guided CNB from January 2010 to December 2017 and identified 316 underestimated IC cases with SLNB. Data on clinical characteristics, radiologic features, and final pathological findings were examined. Twenty-three patients (7.3%) had SLN metastasis. Multivariate analysis indicated that an IC tumor size > 0.5 cm (odds ratio: 3.11, p = 0.033) and the presence of lymphovascular invasion (odds ratio: 32.85, p < 0.0001) were independent risk predictors of SLN metastasis. In the absence of any predictors, the incidence of positive SLNs was very low (2.6%) in the total population and extremely low (1.3%) in the BCS subgroup. Therefore, omitting SLNB may be an acceptable option for patients who initially underwent BCS without risk predictors on final pathological assessment. Further prospective studies are necessary before clinical application.

Disparities in breast cancer presentation and treatment of older women, by insurance status.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e17516-e17516
Author(s):  
Carling Ursem ◽  
Gretchen Genevieve Kimmick ◽  
Roger T. Anderson ◽  
Wenke Hwang ◽  
Fabian Camacho
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Older Women ◽  
Tumor Size ◽  
The Elderly ◽  
Breast Conserving Surgery ◽  
Her2 Status ◽  
Lymph Node Status ◽  
Insurance Status ◽  
Breast Cancers

e17516 Background: Disparities are known to exist in breast cancer outcomes by age and socioeconomic status (SES), but there is little data regarding these disparities in the elderly. We studied older women in North Carolina (NC) using insurance status as an indicator of SES. Methods: From the 1999-2002 NC Central Cancer Registry, we identified women age ≥65 years presenting with nonmetastatic breast cancer, having surgery within 60 days of diagnosis, no neoadjuvant therapy, and insured by Medicare only (M) or dual Medicaid/Medicare (dMM). Chi-square tests followed by Tukey Style Multiple Comparison of Proportions were used to compare baseline characteristics and treatment received. Multivariate analyses including age, race, Charlson comorbidity, tumor size, lymph node status (LN), ER/PR status, HER2 status, and relevant treatment components, were used to determine predictors of use of chemotherapy. Results: The study population, n=3088 with mean age 75 (SD 6.69) years, included 560 dMM and 2528 M insured women. In dMM, tumors were larger (23.5 mm vs 18.5 mm, p<0.001), more likely poorly differentiated (p=0.04), and node positive (p=0.004). dMM were significantly less likely to have breast conserving surgery (vs mastectomy, p<0.001), radiation therapy after surgery (<0.001), adjuvant chemotherapy (0.007), and adjuvant endocrine therapy (<0.001). Significant predictors of receipt of adjuvant chemotherapy were: for dMM, white race (OR 0.22, 95% CI 0.06-0.78), positive LN (vs negative LN; 6.00, 1.44-25.02); for M, age 65-69 (vs 75+; 7.43, 3.64-15.18), age 70-74 (vs 75+; 4.93, 95% CI 2.38-10.22), larger tumor size (1.73, 1.09-2.74), positive LN (9.25, 4.80-17.83), and ER/PR negative (4.98, 2.29-10.85). Conclusions: Breast cancers in low SES, older patients are higher grade, larger, and more advanced, yet they less often receive adjuvant chemotherapy. Future work should focus on interventions to increase receipt of standard of care treatment among this population.

The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 581-581
Author(s):  
Alison Laws ◽  
Ricardo G. Pastorello ◽  
Jungeon Choi ◽  
Olga Kantor ◽  
Samantha Grossmith ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Neoadjuvant Chemotherapy ◽  
Treatment Effect ◽  
Tumor Response ◽  
Residual Disease ◽  
Breast Conserving Surgery ◽  
Invasive Disease ◽  
Post Treatment ◽  
The Impact

581 Background: Residual disease after neoadjuvant chemotherapy (NAC) is a poor prognostic factor. The relationship between the pattern of tumor response and other post-treatment histologic features on local recurrence (LR) is not well studied. Methods: We identified 380 patients (pts) treated with NAC, breast-conserving surgery and radiation from 2002-2014. Pts with available surgical slides underwent detailed pathology review. Pathologic complete response (pCR) was defined as no invasive or in situ disease in the breast or axilla. Pattern of tumor response was defined as: none, scattered, or concentric. The degree of treatment effect was categorized as: absent, mild or marked. Univariate (UVA) and multivariate analyses (MVA) were performed to identify factors associated with LR. Results: 243 (64%) cases had complete slides available and formed the study cohort. 76 (31%) were ER+/HER2-, 90 (38%) ER-/HER2- and 77 (31%) HER2+. 98% of HER2+ pts received neoadjuvant trastuzumab; 89% of ER+ pts received adjuvant endocrine therapy. At median follow-up of 75 months, 10/243 (4.1%) pts had LR and 5-yr LR-free survival was 95.7%. LR occurred in 1/76 (1.3%) pts with breast pCR, 1/19 (5.2%) with residual DCIS, and 8/148 (5.4%) with residual invasive disease; including 6/78 (7.7%) with scattered tumor response, 2/46 (4.3%) with concentric response and 0/24 with no response. On UVA, age (OR < 50 vs ≥50 5.9, p = 0.03) and residual DCIS with comedonecrosis (OR 8.2, p < 0.01) were significantly associated with LR. Presence of tumor bed at the margin (OR 4.6, p = 0.06) approached significance. The odds of LR were higher with scattered regression (OR 1.83 vs. concentric, p = 0.47) and lower with breast pCR (OR 0.23, p = 0.17), but these results were not statistically significant. Multicentric disease, receptor status, ypT, ypN, RCB score, degree of treatment effect, high-grade residual invasive disease, margin status of residual disease and lymphovascular invasion were not associated with LR (all p > 0.05). Age (OR < 50 vs ≥50 7.4, p = 0.04) and residual DCIS with comedonecrosis (OR 7.5, p = 0.02) remained significant on MVA. Conclusions: With modern systemic therapy, LR rates after NAC, breast-conserving surgery and radiation are low, with less than 5% of patients experiencing a LR after a median follow-up of over 6 years. Young age and residual DCIS with comedonecrosis were associated with LR, but not pattern of tumor response.

Sign in / Sign up

Export Citation Format

Share Document